How much clinical trial insurance does a gene therapy trial need?

Gene therapy carries the highest per-subject uncertainty in clinical research. The intervention usually cannot be reversed or withdrawn once administered, the mechanism (for example an integrating viral vector) is novel, and the trial populations are frequently rare-disease, pediatric, or otherwise vulnerable. Each of those factors pushes both the required limit and the underwriting scrutiny up.

First-in-human and early-phase gene-therapy trials commonly require $10M-$25M in clinical trial liability, and pivotal, multi-country, or oncology gene-therapy programs push higher. These are practitioner-typical ranges; the controlling number is what the clinical trial agreement, the IRB or ethics committee, and any applicable national law specify for the particular study.

Gene-therapy programs frequently carry both an aggregate limit for the whole trial and a per-subject (per-claimant) sub-limit, set so a single catastrophic injury can be funded without exhausting the aggregate that protects the rest of the cohort. Ethics committees and, in some countries, national regulators review the insurance and subject-compensation arrangements before enrollment, and inadequate limits can hold up approval.

FDA guidance calls for long-term follow-up of gene-therapy subjects for as long as 15 years, to detect delayed events such as insertional oncogenesis. Most clinical trial liability is claims-made, so it only responds to claims reported while coverage or a tail is in force. A sponsor that sizes the limit correctly but lets the claims-made policy lapse at close-out has left the long-tail window uninsured.

The right structure is continuous claims-made coverage with the retroactive date preserved across renewals and carrier changes, plus a long extended reporting period (tail) purchased at close-out. Gene-therapy tail is expensive relative to other indications and should be budgeted from the outset.

Clinical trial liability is one line in a cell and gene therapy program that also carries D&O, products and completed operations as the therapy nears commercialization, manufacturing-related property and cargo coverage, and cyber. Sizing the trial liability without confirming the tail budget and the products transition is a common gap. Reading the full CTA insurance schedule, and planning the tail, belongs in the same conversation as the limit.